Studies have shown that active fund managers routinely underperform the S&P500 index*​

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)

VRTX Stock Predictions and Ratings

WSX Rating:
STRONG BUY
WSX Forecast (1yr):
15%
Analyst Rating:
BUY
Analyst Forecast (1yr):
13%

VRTX Stock Analysis

VRTX PE Ratio: 25.4

VRTX PEG Ratio: 2.1

VRTX Forward EPS Growth (12 month): 12.30%

VRTX PS Ratio: 8.9

VRTX PSG Ratio: 0.9

VRTX Forward Revenue Growth (12 month): 9.90%

VRTX Articles

No data was found